InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-30 | 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. | Director | Purchase | 971.1K | $6.50 | $6.31M | 26.98M | View ↗ | |
| 2026-03-27 | 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. | Director | Purchase | 2.50M | $6.43 | $16.05M | 26.00M | View ↗ | |
| 2026-03-26 | 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. | Director | Purchase | 5.31M | $6.08 | $32.27M | 23.51M | View ↗ | |
| 2026-02-26 | 2026-02-27 | Francis Chris | See Remarks | Sale | 33.2K | $15.05 | $500K | 61.9K | View ↗ | |
| 2026-02-09 | 2026-02-11 | Moran Kyle | Chief Financial Officer | Sale | 3,588 | $13.45 | $48K | 134.4K | View ↗ |
No annual data found.
Should WVE-006’s RNA-Editing AAT Data Shift the Risk-Reward Calculus for Wave Life Sciences (WVE) Investors?
Wave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD Data
Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1